Abstract: An apparatus for activating a physical card in a virtual environment comprises a processor associated with a server. The processor is configured to receive a request to issue a physical card to a first user and to generate a first non-fungible token (NFT) for storage in the physical card, wherein the first NFT is then displayed as a digital card in a virtual environment. The processor is further configured to receive the digital card in an interaction and to generate a second NFT. The processor is further configured to combine the first NFT and the second NFT to generate an activation NFT that allows the physical card to access a profile corresponding to the first user during an interaction. The processor is further configured to transmit the activation NFT and an instruction to the first user device to store the activation NFT in the physical card.

Abstract: The present application relates to a pharmaceutical composition/formulation for improving or preventing progression of chronic kidney disease (CKD) caused due to inflammation and/or Klotho under expression. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Palmitoylethanolamide (PEA), Cholecalciferol and one or more natural ingredients. The invention also provides various formulations and methods of preparing the same.

Abstract: The present invention relates to a pharmaceutical composition/formulation for use in treatment of Iron Deficiency Anaemia (IDA), Anaemia of Inflammation (AOI) and neuro-degenerative disorders. More particularly, the invention relates to a pharmaceutical composition/formulation comprising a synergistic combination of Lactoferrin and Guanosine Nucleotides or a pharmaceutically acceptable salt thereof. The application also provides various formulations and methods of preparing the same.

Abstract: Aspects described herein relate to obtaining, by a device, access point name (APN) information corresponding to a network entity, the APN information indicating one or more available APNs, determining whether at least one APN of the one or more available APNs indicated in the obtained APN information matches authorized APN information stored in the device, and prohibiting communications for the device that correspond to the at least one APN based at least in part on the determination that the at least one APN is not indicated in the authorized APN information.

Abstract: The present invention relates to a pharmaceutical composition/formulation for the prevention of diet induced obesity. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Oleoylethanolamide (OEA) and other natural ingredients can be used for treatment of obesity and its related disorders associated with fat metabolism like non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD). This can also be helpful in controlling obesity by way of maintaining body weight. The invention also provides various formulations and methods of preparing the same.

Abstract: Aspects described herein relate to obtaining, by a device, access point name (APN) information corresponding to a network entity, the APN information indicating one or more available APNs, determining whether at least one APN of the one or more available APNs indicated in the obtained APN information matches authorized APN information stored in the device, and prohibiting communications for the device that correspond to the at least one APN based at least in part on the determination that the at least one APN is not indicated in the authorized APN information.

Abstract: In an aspect of the present disclosure, a method, a computer-readable medium, and an apparatus are provided to overcome the deficiencies discussed above. The apparatus may include a frontend component and a storage element. The frontend component may include a processor configured to communicate with a second device and to receive a signal from the second device, the signal providing power to the apparatus and providing profile information. The storage element may be coupled to the frontend component and may be configured to receive the profile information and to store the profile information while powered by the frontend component through the signal from the second device.

Abstract: The present application relates to a pharmaceutical composition/formulation for improving or preventing progression of chronic kidney disease (CKD) caused due to inflammation and/or Klotho under expression. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Palmitoylethanolamide (PEA), Cholecalciferol and one or more natural ingredients. The invention also provides various formulations and methods of preparing the same.

Abstract: In an aspect of the present disclosure, a method, a computer-readable medium, and an apparatus are provided to overcome the deficiencies discussed above. The apparatus may include a frontend component and a storage element. The frontend component may include a processor configured to communicate with a second device and to receive a signal from the second device, the signal providing power to the apparatus and providing profile information. The storage element may be coupled to the frontend component and may be configured to receive the profile information and to store the profile information while powered by the frontend component through the signal from the second device.

Abstract: The present invention relates to a pharmaceutical composition/formulation for the prevention of diet induced obesity. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Oleoylethanolamide (OEA) and other natural ingredients can be used for treatment of obesity and its related disorders associated with fat metabolism like non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD). This can also be helpful in controlling obesity by way of maintaining body weight. The invention also provides various formulations and methods of preparing the same.

Abstract: The present application describes a pharmaceutical composition/formulation for use in controlling neuropathic pain. The composition/formulation includes Palmitoylethanolamide (PEA) and one or more natural ingredients. The application also provides various formulations and methods of preparing the same.

Abstract: In an embodiment, a method comprises receiving an input defining organization of one or more universal data elements; generating a universal schema that defines organization of the one or more universal data elements based on the input; associating the universal schema with a specialized plug-in, wherein the specialized plug-in maps the one or more universal data elements with data elements in one or more specialized databases maintained by a specialized data store; receiving, from a computer, a request to receive data stored in the specialized data store and comprising parameters based on the universal schema; transforming the request using the specialized plug-in to produce a specialized query; sending the specialized query to the specialized data store to execute the specialized query; receiving a specialized result set from the specialized data store; sending, to the computer, a result set based on specialized result set.

Abstract: A method for switching a Universal Integrated Circuit Card (UICC) transmission protocol includes: setting an operational mode of the UICC to an ISO 7816-12 USB UICC transmission protocol mode (USB mode); and in response to a user input, enabling the UICC to fallback from the USB mode to an ISO 7816-3 T=0/T=1 transmission protocol mode (ISO mode).

Abstract: In an embodiment, a method comprises receiving an input defining organization of one or more universal data elements; generating a universal schema that defines organization of the one or more universal data elements based on the input; associating the universal schema with a specialized plug-in, wherein the specialized plug-in maps the one or more universal data elements with data elements in one or more specialized databases maintained by a specialized data store; receiving, from a computer, a request to receive data stored in the specialized data store and comprising parameters based on the universal schema; transforming the request using the specialized plug-in to produce a specialized query; sending the specialized query to the specialized data store to execute the specialized query; receiving a specialized result set from the specialized data store; sending, to the computer, a result set based on specialized result set.

Abstract: Systems and methods are provided that record details and analytics about a sales call presentation. After a sales call presentation is initiated, a recording is started to record the analytics of the sales call presentation. After an additional party joins the presentation, a second analytical recording is initiated with respect to the additional party. Accordingly, accurate analytical data for the additional party may be obtained.